2nd Next Generation Sequencing
for Adventitious Virus Detection
An IABS-EU Meeting
This meeting will focus on the current scientific data and knowledge related to the use of next generation sequencing technologies for adventitious virus detection in biological products. Discussions will include ongoing efforts and future needs toward standardization and validation of the technical and bioinformatics steps involved in NGS for its applications in characterization and safety evaluation of biologics, including human and animal vaccines. The meeting will bring together representatives from industry, academia, technology providers, and international regulatory bodies for developing a scientific consensus regarding readiness of NGS for detection of adventitious viruses in biologics.
Abstracts will be considered for talks/posters.
Approx: 500 words
Submission deadline: May 31, 2019.
Subject: Abstract for 2nd IABS NGS meeting
The following topics related to NGS for human and veterinary biologics will be considered:
Sample preparation and processing
Standards and Standardization
Bioinformatics strategies and pipelines
Follow up of signals
Applications for adventitious virus testing in biologics
Dieter Deforce, Ghent University / Federal Agency for Medicines and Health Products of Belgium (FAMHP)
Sebastiaan Theuns, Ghent University
Arifa Khan, U.S. Food and Drug Administration (FDA)
Pieter Neels, International Alliance for Biological Standardization (IABS)
Sven Arnouts, Ghent University / PROVAXS
Johannes Blümel, Paul-Ehrlich Institut (PEI)
William Egan, GlaxoSmithKline Vaccines
Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Ivana Knezevic, World Heath Organization (WHO)
Laurent Mallet, Sanofi Pasteur
Gerald Schumann, Paul-Ehrlich Institut (PEI)
Joseph Victoria, Boehringer-Ingelheim
More information about this IABS-EU meeting coming soon...